Skip to main content
. Author manuscript; available in PMC: 2022 May 3.
Published in final edited form as: Sci Transl Med. 2021 Oct 20;13(616):eabj1008. doi: 10.1126/scitranslmed.abj1008

Figure 7. RBC-bound mtDNA is elevated in COVID-19.

Figure 7.

(A) RBC-bound mtDNA was measured in healthy donors and patients hospitalized with COVID-19 at day 0 and day 7 of study enrollment. Data were analyzed by a Kruskal-Wallis test with Dunn’s correction for multiple comparisons. (B) RBC-bound mtDNA in patients was stratified by disease severity. Data were analyzed using a Kruskal Wallis test with Dunn’s correction for multiple comparisons. (C to E) The correlation between RBC-bound mtDNA and hemoglobin for all patients (C), patients with severe disease (D) and patients with moderate disease (E) are shown. Statistical analysis was done using Spearman rank correlation. (F to H) RBC-bound mtDNA was evaluated in patients stratified by median hemoglobin. Data are shown for all patients (F), patients with severe disease (G), and patients with moderate disease (H). Data in (F to H) were analyzed by Mann-Whitney tests. (I) A correlation between Apache III score and RBC-bound mtDNA is shown for COVID-19 patients. Statistical analysis was done using a Pearson’s correlation (J) RBC-bound mtDNA was measured in COVID-19 patients stratified into quartiles based on Apache III score. Data were analyzed by a one-way ANOVA. For all panels, *P<0.05, **P<0.01, ***P<0.005, and ****P<0.001 denote significant findings.